SecBot SecBot
6-K ·Filed Jul 15, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001434265-26-000102
Notable filing: 6-K
Actionable Insight • Neutral

Monitor Genmab's upcoming earnings release for royalty revenue recognition and any guidance updates. The DARZALEX sales trajectory is a key indicator of Genmab's financial health, but this filing alone provides no comparative data or forward-looking statements.

DirectionNeutral
Confidencehigh
Horizondays

DARZALEX

▲ Bullish Named in this 6-K
Impact
Phase
Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
Time to market
Already approved and on the market — DARZALEX (IV) since Nov 2015 and DARZALEX FASPRO (subcutaneous) since May 2020; label expansion for newly diagnosed multiple myeloma added ~Jan 2026.
Next catalyst
None dated

What to watchFor JNJ shareholders, DARZALEX is a cash-cow growth driver, not a binary, treat it as part of the Innovative Medicine growth story (with CARVYKTI, TREMFYA, SPRAVATO) that supported the FY2026 guidance raise, and watch each Genmab 6-K for quarterly DARZALEX net sales as the cleanest read on the franchise. The bigger near-term event to track is competitive: Bristol Myers' iberdomide + daratumumab + dexamethasone PDUFA landed Aug 17, 2026, and BMY's bb2121 CAR-T Phase 3 readout is pending.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.08
T+0 close · Jul 15, 2026 · via day close
Latest settled
+23.97%
T+60 · $36.05
Vs SPY
+21.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $29.08entry
  2. T+1 · 4mo ago −0.34%α +0.20% · $28.98
  3. T+5 · 4mo ago −0.79%α +0.19% · $28.85
  4. T+20 · 3mo ago +8.05%α +5.70% · $31.42
  5. T+60 · 6w ago +23.97%α +21.44% · $36.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab disclosed Q2 2026 worldwide net sales of DARZALEX at USD 4,207 million, with USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. The company receives royalties on these sales from Johnson & Johnson. This is a routine quarterly sales update without comparative data or guidance, providing a top-line indicator of Genmab's primary revenue driver.

Key Facts

  • Worldwide net trade sales of DARZALEX in Q2 2026 totaled USD 4,207 million.
  • U.S. net sales were USD 2,435 million; rest of world net sales were USD 1,772 million.
  • Genmab receives royalties on worldwide DARZALEX sales under its license with Johnson & Johnson (Janssen).

Financial Impact

DARZALEX Q2 2026 net sales of USD 4,207 million; Genmab's royalty revenue depends on these sales, but the filing does not disclose Genmab's own financials.

royalty revenueproduct sales

Risk Factors

  • Heavy reliance on DARZALEX royalties for revenue.
  • Potential competition from biosimilars or alternative therapies.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000102
Document: gmab_20260715x6k.htm0001434265-26-000102
Document: 0001434265-26-000102-index-headers.html0001434265-26-000102
Document: 0001434265-26-000102-index.html0001434265-26-000102
Document: 0001434265-26-000102.txt0001434265-26-000102

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026